Overcoming antifungal resistance in Candida albicans via RNA interference: a therapeutic perspective

Area of Science:

• Mycology
• Molecular Biology
• Antimicrobial Resistance

Background:

• Candida albicans is a major cause of hospital-acquired infections.
• Antifungal resistance is a growing global health concern, limiting treatment options.
• Existing therapies face challenges due to resistance mechanisms like efflux pump overexpression and ergosterol pathway mutations.

Purpose of the Study:

• To explore the potential of RNA interference (RNAi) as a therapeutic strategy against drug-resistant Candida albicans.
• To review established antifungal targets and emerging RNAi-based gene silencing methods.
• To identify potential molecular targets for RNAi therapy in C. albicans.

Main Methods:

• Review of current literature on Candida albicans antifungal resistance.
• Exploration of RNA interference (RNAi) mechanisms and applications in fungal pathogens.
• Identification and discussion of potential molecular targets for RNAi, including ERG1, ERG6, ERG11, CDR1, CDR2, CLB2, and GSC1.

Main Results:

• RNAi has demonstrated efficacy in other fungal pathogens, but its application in C. albicans is nascent.
• Potential molecular targets for RNAi in C. albicans have been identified, including genes involved in ergosterol biosynthesis and drug resistance.
• RNAi can overcome resistance at the transcriptional level, bypassing post-translational resistance mechanisms.

Conclusions:

• RNA interference presents a novel therapeutic avenue to combat resistant Candida albicans.
• Advances in siRNA design, chemical modifications, and delivery systems are crucial for RNAi-based antifungal therapies.
• RNA-based therapeutics hold the potential to revolutionize the treatment of challenging fungal infections.